Introducing SHL’s first White Paper: “Auto Injectors: From Planning to Launch”
SHL is introducing the company’s first White Paper on autoinjectors with the goal of sharing with readers insights on how to prepare for the overall project.
Deerfield Beach, FL, January 05, 2012 --(PR.com)-- SHL is officially introducing the company’s first White Paper on the topic of “Auto Injectors; From Planning to Launch” with the goal of sharing with readers insights on how to prepare for the overall development process from different perspectives including design, regulatory and manufacturing.
The paper does not have any promotional content and focuses on sharing with those interested in starting an auto injector project what to prepare for and challenges to look out for. As a preview, please see the paper's introduction snippet as below:
Looking at the rising trend towards self-administration therapies, injectable drug delivery devices such as pen injectors, auto injectors and needle free injectors show a significant growth potential in the near future.
In 2010, the pen systems and auto injectors market was estimated to be worth over $0.58bn, a growth of 8-10% from previous years. It is estimated that the market will continue to grow steadily between 10-15% over the forecast period. It will reach $0.87bn in 2013 and $1.07bn in 2015.
(Please refer to figure and corresponding reference in the actual paper.)
Driven by the corresponding industry demands, biopharmaceutical companies have since introduced a large range of solutions for delivery of injectable drugs and continue to push for improvements in every aspect. In fact, industry analysts have estimated that over 30% of all new product submissions to the FDA are combination products (Richter, 2011). Of these, the auto injector is one of the fastest emerging drug delivery solutions that enhance patient experience and compliance by allowing them to safely self-administer medications at home. Aside from patient benefits, the resulting reduced number of clinic visits can help lower cost for health authorities by removing burden on nurses/Healthcare Providers (HCPs) to deliver face to face treatments. The various ergonomic designs and safety mechanisms built into the auto injector also help address patient dexterity concerns and minimize the possibility of needle-stick injuries for HCPs assisting with the delivery.
While the auto injector is now often considered by many biopharmaceutical companies to be a suitable device to commercially launch their therapeutic drugs in, to do so successfully requires detailed planning, combination product knowledge, regulatory awareness and even more importantly, close collaboration with a carefully chosen device manufacturer. Unfortunately, biopharmaceutical and device companies have different product lifecycles and development processes which can lead to process gaps that are crucial to the overall project and can ultimately influence the product’s speed to market. It is therefore imperative that the biopharmaceutical company has a thorough understanding of all related processes, when and where to involve the device manufacturer, how to meet the corresponding regulatory demands for combination products, what core competencies to seek for and more.
This white paper focuses on assisting biopharmaceutical companies in taking a closer look at the development process of the secondary packaging of an auto injector project from planning to launch and best practices on how to prepare for and address potential challenges along the way.
Download Full Paper Here: (http://www.shl-group.com/en/downloads/others.html).
About SHL
SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 1,800 staff globally (1000+ staff in Taiwan), with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia.
SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Our organization consists of three distinct group companies:
SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies.
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use.
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products.
For additional information visit www.shl-group.com or contact us at info@shl-group.com.
SHL Media Contact
Steven R. Kaufman
Marketing Director
pr@shl-group.com
###
The paper does not have any promotional content and focuses on sharing with those interested in starting an auto injector project what to prepare for and challenges to look out for. As a preview, please see the paper's introduction snippet as below:
Looking at the rising trend towards self-administration therapies, injectable drug delivery devices such as pen injectors, auto injectors and needle free injectors show a significant growth potential in the near future.
In 2010, the pen systems and auto injectors market was estimated to be worth over $0.58bn, a growth of 8-10% from previous years. It is estimated that the market will continue to grow steadily between 10-15% over the forecast period. It will reach $0.87bn in 2013 and $1.07bn in 2015.
(Please refer to figure and corresponding reference in the actual paper.)
Driven by the corresponding industry demands, biopharmaceutical companies have since introduced a large range of solutions for delivery of injectable drugs and continue to push for improvements in every aspect. In fact, industry analysts have estimated that over 30% of all new product submissions to the FDA are combination products (Richter, 2011). Of these, the auto injector is one of the fastest emerging drug delivery solutions that enhance patient experience and compliance by allowing them to safely self-administer medications at home. Aside from patient benefits, the resulting reduced number of clinic visits can help lower cost for health authorities by removing burden on nurses/Healthcare Providers (HCPs) to deliver face to face treatments. The various ergonomic designs and safety mechanisms built into the auto injector also help address patient dexterity concerns and minimize the possibility of needle-stick injuries for HCPs assisting with the delivery.
While the auto injector is now often considered by many biopharmaceutical companies to be a suitable device to commercially launch their therapeutic drugs in, to do so successfully requires detailed planning, combination product knowledge, regulatory awareness and even more importantly, close collaboration with a carefully chosen device manufacturer. Unfortunately, biopharmaceutical and device companies have different product lifecycles and development processes which can lead to process gaps that are crucial to the overall project and can ultimately influence the product’s speed to market. It is therefore imperative that the biopharmaceutical company has a thorough understanding of all related processes, when and where to involve the device manufacturer, how to meet the corresponding regulatory demands for combination products, what core competencies to seek for and more.
This white paper focuses on assisting biopharmaceutical companies in taking a closer look at the development process of the secondary packaging of an auto injector project from planning to launch and best practices on how to prepare for and address potential challenges along the way.
Download Full Paper Here: (http://www.shl-group.com/en/downloads/others.html).
About SHL
SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 1,800 staff globally (1000+ staff in Taiwan), with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia.
SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Our organization consists of three distinct group companies:
SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies.
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use.
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products.
For additional information visit www.shl-group.com or contact us at info@shl-group.com.
SHL Media Contact
Steven R. Kaufman
Marketing Director
pr@shl-group.com
###
Contact
SHL Group (Scandinavian Health Group Ltd)
Steven Kaufman
+886-3-2170303
www.shl-group.com
Steven Kaufman
+886-3-2170303
www.shl-group.com
Contact
Categories